三氧化二砷与沙利度胺联合治疗骨髓增生异常综合征的效果研究

Effect of Arsenic Trioxide combined with Thalidomide in the Treatment of Myelodysplastic Syndrome

目的研究三氧化二砷与沙利度胺联合治疗骨髓增生异常综合征的临床治疗效果。方法选取我院2016年1月至2019年1月收治的骨髓增生异常综合征患者60例,按照随机数字表法分为对照组和观察组。每组各30例,对照组采用沙利度胺进行治疗,观察组采用三氧化二砷联合沙利度胺进行治疗,观察对比两组患者的治疗效果、用药前和用药后2个月患者中性粒细胞的绝对值、血红蛋白、血小板计数以及不良反应的发生情况。结果观察组患者用药前的中性粒细胞的绝对值、血红蛋白、血小板计数及治疗过程中的不良反应的发生情况均与对照组患者无明显差异(P>0.05),不具有统计学意义,但观察组患者的治疗效果、用药两个月后中性粒细胞的绝对值、血红蛋白、血小板计数均明显优于对照组(P>0.05),差异具有统计学意义。结论三氧化二砷与沙利度胺联合治疗骨髓增生异常综合征的临床治疗效果优于单一使用沙利度胺,可有效改善患者的病情,并提高患者的身体免疫功能,且安全性较高,值得临床的推广与应用。

Objective To study the clinical effect of arsenic trioxide combined with thalidomide in the treatment of myelodysplastic syndrome.Methods 60 patients with myelodysplastic syndrome admitted to our hospital from January 2016 to January 2019 were divided into control group and observation group according to random number table method.Thirty patients in each group were treated with thalidomide in the control group,while the observation group was treated with arsenic trioxide combined with thalidomide.The therapeutic effect,absolute value of neutrophils,hemoglobin,platelet count and adverse reactions of the two groups were observed and compared.Results The absolute value of neutrophils,hemoglobin,platelet count and adverse reactions of the patients in the observation group before medication were not significantly different from those in the control group(P>0.05),but there was no statistical significance in the treatment effect of the patients in the observation group and neutrophil extinction after two months of medication.Pair value,hemoglobin,platelet count were significantly better than the control group(P>0.05),with statistical significance.Conclusion The clinical effect of arsenic trioxide combined with thalidomide in the treatment of myelodysplastic syndrome is better than thalidomide alone.It can effectively improve the patient’s condition and improve the patient’s immune function,and has high safety,which is worthy of clinical promotion and application.